Tolbutamide and gliclazide block the K ATP channel K ir 6.2/Sur1, causing membrane depolarization and stimulating insulin secretion in pancreatic beta cells. We examined the ability of the EPAC-selective cAMP analog 8-pCPT-29-O-Me-cAMP-AM to potentiate the action of these drugs and the mechanism that might account for it. Insulin secretion stimulated by both 200 mM tolbutamide and 20 mM gliclazide, concentrations that had equivalent effects on membrane potential, was inhibited by thapsigargin (1 mM) or the L-type Ca 21 channel blocker nicardipine (2 mM) and was potentiated by 8-pCPT-29-O-MecAMP-AM at concentrations $2 mM in INS-1 cells. Ca 21 transients stimulated by either tolbutamide or gliclazide were inhibited by thapsigargin or nicardipine and were significantly potentiated by 8-pCPT-29-O-Me-cAMP-AM at 5 mM but not 1 mM. Both tolbutamide and gliclazide stimulated phospholipase C activity; however, only gliclazide did so independently of its activity at K ATP channels, and this activity was partially inhibited by pertussis toxin. 8-pCPT-29-O-Me-cAMP-AM alone (5 mM) did not stimulate insulin secretion, but did increase intracellular Ca 21 concentration significantly, and this activity was inhibited by 25 mM 2-aminoethoxydiphenylborate (2-APB) or the removal of extracellular Ca 21 . 8-pCPT-29-OMe-cAMP-AM potentiation of insulin secretion stimulated by tolbutamide was markedly inhibited by 2-APB (25 mM) and enhanced by the PKC inhibitor bisindolylmaleimide I (1 mM). Our data demonstrate that the actions of both tolbutamide and gliclazide are strongly potentiated by 8-pCPT-29-O-MecAMP-AM, that gliclazide can stimulate phospholipase C activity via a partially pertussis toxin-sensitive mechanism, and that 8-pCPT-29-O-Me-cAMP-AM potentiation of tolbutamide action may involve activation of a 2-APB-sensitive Ca 21 influx.
Introduction
Sulfonylurea drugs, such as tolbutamide and gliclazide, have been used for decades to stimulate insulin secretion and decrease blood glucose levels in type 2 patients with diabetes with insufficient endogenous insulin secretion (Groop, 1992) . These drugs bypass the metabolic steps required for glucosestimulated insulin secretion and mimic the effect of an increase in ATP/ADP ratio (Rorsman and Trube, 1985; Dunne and Petersen, 1986) on the K ATP channel composed of the K ir 6.2 and SUR1 subunits (Babenko et al., 1998) . Binding of sulfonylureas to the K ATP channel favors channel closing (Schmid-Antomarchi et al., 1987) and subsequent membrane depolarization because open K ATP channels permit the efflux of K 1 ions and the maintenance of the membrane potential close to the equilibrium potential for K 1 (Cook and Hales, 1984) . Depolarization of the membrane potential of pancreatic beta cells leads to the activation of several varieties of voltagegated Ca 21 channels (Horvath et al., 1998) , including the L-type channels Ca v 1.2 and Ca v 1.3 (Seino et al., 1992) . The subsequent rise in intracellular Ca 21 triggers the exocytosis of insulin (Wollheim et al., 1975) via dense core vesicles that are shuttled to (Van Obberghen et al., 1975) , and eventually fuse with, the plasma membrane (Barg et al., 2001; Shibasaki et al., 2007) .
Recently, exchange protein directly activated by cAMP 2 (EPAC2) was identified as a novel cellular target for some members of the sulfonylurea drug class . EPAC2 is a guanine nucleotide exchange factor (GEF) for the low molecular weight GTP binding protein Rap1 (Kawasaki et al., 1998) . In the cAMP-bound form, EPAC2 accelerates the exchange of GDP for GTP at the nucleotide binding site of Rap1 (Kawasaki et al., 1998) . Along with the activation of protein kinase A (Ding and Gromada, 1997) , activation of EPAC2 contributes to the potentiation of glucose-stimulated insulin secretion by incretin hormones that stimulate adenylyl cyclase activity, such as GLP-1 (Leech et al., 2010a) . The GTPbound form of Rap1 is implicated in the activation of phospholipase C-« in pancreatic beta cells, in augmenting the number of insulin granules in close proximity to sites of exocytosis on the plasma membrane (Shibasaki et al., 2007) , and in the priming of insulin granules for exocytosis (Eliasson et al., 2003) .
EPAC2 is thought to exist in a signaling complex with several other peripheral membrane proteins. EPAC2 interacts directly with SUR1 (Shibasaki et al., 2004) and with the CAZ protein piccolo (Fenster et al., 2000) , which forms a dimer with the related protein RIM2 (Wang et al., 2000) , in a Ca 21 -dependent manner (Fujimoto et al., 2002) . In addition, the voltage-gated Ca 21 channel Ca v 1.2 interacts with the C2 domains of RIM2 and piccolo via the intracellular II-III loop (Shibasaki et al., 2004) . This signaling complex of scaffolding proteins (RIM2, piccolo), cAMP effector (EPAC2), and ion channel subunits (SUR1, Ca v 1.2) is of special significance because membrane depolarization-dependent calcium influx via Ca v 1.2 channels has been implicated in triggering Ca 21 -induced Ca 21 release from the ER in pancreatic beta cells (Liu et al., 2006) , a process that is amplified by cAMP, at least in part, through EPAC2 (Kang et al., 2003; Liu et al., 2006) . The role of intrinsic EPAC2 stimulation by sulfonylureas on insulin secretion or the underlying Ca 21 dynamics in beta cells is currently unknown.
Tolbutamide and gliclazide, which both stimulate insulin secretion from pancreatic beta cells by block of K ATP channels, differ in their ability to bind and activate EPAC2. Zhang et al. (2009) , reported that tolbutamide at concentrations $30 mM significantly activated Rap1 in an EPAC2-dependent manner, whereas gliclazide at concentrations up to 30 nM did not. We used electrophysiological analysis to identify concentrations of tolbutamide and gliclazide that had equivalent effects on K ATP channel activity both in terms of block of current and induction of membrane depolarization. We then used these concentrations of tolbutamide and gliclazide to compare stimulation of insulin secretion, stimulation of increases in intracellular Ca 21 concentration, and potentiation of these activities by the EPAC-selective cAMP analog (ESCA) 8-pCPT-29-O-MecAMP-AM in INS-1 cells. Because activation of phospholipase C is a consequence of EPAC2 activation in pancreatic beta cells, we also assayed phospholipase C activation by tolbutamide and gliclazide in the absence and presence of diazoxide to prevent membrane depolarization and Ca 21 influx via voltage-gated Ca 21 channels. To gain insight into the mechanism whereby EPAC activation potentiates sulfonylurea action, we assayed 8-pCPT-29-O-Me-cAMP-AM modulation of phospholipase C activity and intracellular Ca 21 concentration in INS-1 cells.
Materials and Methods
Chemicals. U73122 and U73343 were from Tocris (Minneapolis, MN). 8-pCPT-29-O-Me-cAMP and 8-pCPT-29-O-Me-cAMP-AM were from Biolog (Bremen, Germany). Rp-cAMP was from Santa Cruz Biotechnology (Santa Cruz, CA). Ryanodine was from Calbiochem (San Diego, CA). All other chemical reagents were obtained from Sigma-Aldrich (St. Louis, MO).
Cell Culture. INS-1 cells were grown in RPMI medium (SigmaAldrich) supplemented with 10% fetal bovine serum (HyClone, Logan, UT), 11 mg/ml sodium pyruvate, 10 mM HEPES, 100 U/ml penicillin, 100 mg/ml streptomycin, and 50 mM/b-mercaptoethanol at 37°C, 5% CO 2 .
Electrophysiological Assay. Electrophysiological measurements in INS-1 cells were recorded at room temperature using an Axopatch 200B amplifier (Molecular Devices, Sunnyvale, CA) and filtered at 1 kHz (six-pole Bessel filter, 23 dB). Electrodes were pulled from borosilicate glass (VWR, West Chester, PA) and fire-polished to resistances of 2-5 MV. For current-clamp experiments and voltageclamp experiments to measure K ATP channel current, the intracellular solution contained (in mM) 90 K 2 SO 4 , 10 NaCl, 1 MgCl 2 , 1.1 EGTA, 0.1 CaCl 2 , 5 HEPES, 0.3 ATP, 0.2 GTP. The extracellular solution used for measuring K ATP currents contained (in mM) 138 NaCl, 5.6 KCl, 11.1 glucose, 10 HEPES, 1.2 MgCl 2, 2.6 CaCl 2 , and the same solution with the addition of 2.5 mM glucose was used in current-clamp experiments. The pH of solutions was adjusted to 7.4 with NaOH, and the osmolality was adjusted to 290-300 mOsm. Whole cell K ATP currents were elicited by 1.3-s steps of 620 mV from a holding potential of 270 mV. Data were acquired at a sampling frequency of 1 kHz. The membrane potential of INS-1 cells was measured using gap-free recording at a sampling frequency of 1 kHz in I 5 0 current-clamp mode. The K ATP channel opener, diazoxide (300 mM), was transiently applied to maximally open K ATP channels, before application of tolbutamide or gliclazide. Tolbutamide and gliclazide solutions were prepared from stocks dissolved in 0.1 M NaOH made fresh daily. Diazoxide solutions were prepared from stocks dissolved in DMSO. For recordings of voltage-gated Ca 21 channel currents, the bath solution contained (in mM) 150 Tris, 10 BaCl 2 , 4 MgCl 2 . The intracellular solution contained (in mM) 130 N-methyl-D-glucamine, 10 EGTA, 60 HEPES, 2 ATP, and 1 MgCl 2 . The pH of both solutions was adjusted to 7.3 with methanesulfonic acid, and the osmolality was corrected to 290-300 mOsM. Currentvoltage relationship data were collected by applying 100-ms test depolarizations from 250 to 160 mV in 10-mV increments from a holding potential of 270 mV. Data were acquired at a sampling frequency of 10 kHz and filtered at 1 kHz.
Insulin Secretion Assay. INS-1 cells were plated in 24-well tissue culture plate at 50-70% confluency and incubated overnight in RPMI medium supplemented as described above at 37°C, 5% CO 2 . Immediately before the assay, cells were washed twice in phosphatebuffered saline [PBS: 137 mM NaCl, 10 mM phosphate, 2.7 mM KCl (pH 7.4)], and preincubated with a modified Kreb-Ringer buffer [KRBH: 134 mM NaCl, 3.5 mM KCl, 1.2 mM KH 2 PO 4 , 0.5 mM MgSO 4 , 1.5 mM CaCl 2 , 5 mM NaHCO 3 , 10 mM HEPES (pH 7.4)] supplemented with 0.05% fatty acid free BSA (KRBH buffer) alone or containing indicated concentrations of inhibitors for 30 min at 37°C, 5% CO 2 . The buffer was decanted and replaced with fresh KRBH buffer alone (basal condition) or KRBH containing the indicated concentrations of sulfonylurea with or without inhibitors for 1 hour at 37°C, 5% CO 2 . Secreted insulin was assayed using an ELISA for rat insulin (High-Range EIA kit, ALPCO Diagnostics, Salem, NH). Cells were lysed in 20 mM Na 2 HPO 4 , 150 mM NaCl, 0.1% Triton X-100, 800 nM aprotinin, 50 mM leupeptin, 1 mg/ml pepstatin, 1 mM benzamidine, 1 mM 4-(2-aminoethyl)benzenesulfonylfluoride, 10 mg/ml calpain inhibitor I, and 10 mg/ml calpain inhibitor II (pH 7.4), and cellular protein in each well was determined using the BCA assay (Thermo Scientific, Rockford, IL).
Intracellular Ca 21 Assays. INS-1 cells were plated at 100% confluency in black-walled 96 well plates (Corning Life Sciences, Lowell, MA) in RPMI supplemented as described above, and incubated overnight at 37°C, 5% CO 2 . Cells were washed twice with PBS and incubated with 5 mM Fura-2/acetoxymethyl ester (Fura-2 AM; Molecular Probes, Eugene, OR) diluted in KRBH for 1 hour at 37°C , 5% CO 2 . The KRBH containing Fura-2 AM was then removed, and the cells were washed twice with KRBH and equilibrated for 30 min at 37°C, 5% CO 2 in the KRBH alone, or with indicated concentrations of inhibitors or 8-pCPT-29-O-Me-cAMP-AM. When pertussis toxin was used, 25 ng/well was added to cells in 96-well plates approximately 18 hours before assay. Cells were stimulated by injection of the indicated concentration of sulfonylurea or 8-pCPT-29-O-Me-cAMP-AM (or buffer control), and changes in intracellular Ca 21 concentrations were measured by recording the ratio of fluorescence intensities at 508/20 nm resulting from excitation of Fura-2 at 340/11 nm or 380/20 nm (center/band pass) using a Synergy 4 multi-mode microplate reader (BioTek, Winooski, VT). For experiments injecting sulfonylureas, ratios were acquired every 0.7 s for 15 s before injection and 2 minutes after injection of stimuli. For experiments injecting 8-pCPT-29-O-MecAMP-AM, ratios were acquired every 5 s for 2 minutes before injection and at least 8 minutes after injection. Data were corrected for any injection artifact by subtracting the change in fluorescence ratio measured in cells injected with KRBH alone.
IP 1 Assays. INS-1 cells were plated at approximately 65,000 cells/ well in white 96-well tissue culture plates (PerkinElmer, Waltham, MA) in the presence of 2.5 mM glucose overnight at 37°C and 5% CO 2 . A prestimulation buffer was added to the cells for 1 hour before stimulation [10 mM HEPES, 1 mM CaCl 2 , 0.5 mM MgCl 2 , 4.2 mM KCl, 146 mM NaCl (pH 7.4)]. The prestimulation buffer was decanted, and treatments were made in a stimulation buffer containing LiCl to block inositol phosphate degradation [10 mM HEPES, 1 mM CaCl 2 , 0.5 mM MgCl 2 , 4.2 mM KCl, 146 mM NaCl, 5 mM LiCl (pH 7.4)]. Cells were incubated with treatments for 1 hour at 37°C, 5% CO 2 . When pertussis toxin was used, 25 ng/well was added to cells in 96-well plates approximately 18 hours before assay. IP 1 levels were measured using the IP-One Tb Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF-FRET) Kit from Cisbio (Bedford, MA) according to the manufacturer's instructions. The 620 nm/650 nm fluorescence ratio (excitation wavelength of 330 nM) was measured using a Synergy 4 fluorescent plate reader (BioTek). The concentration of IP 1 in each sample was determined by comparison of the 620 nm/650 nm ratio to those for a standard curve of IP 1 concentrations.
Data Analysis. Data were analyzed using SigmaPlot 11.0. Data are shown as means 6 S.E. Statistical significance was determined using one-way analysis of variance and the Tukey's post hoc test unless otherwise indicated. P , 0.05 was considered significant.
Results
Electrophysiological Characterization of Tolbutamide and Gliclazide Activity in INS-1 Cells. Both tolbutamide and gliclazide bind to and block the K ATP channel in pancreatic beta cells. To compare the effects of these two drugs and determine whether tolbutamide might also activate EPAC2 in INS-1 cells, we determined the potency of K ATP channel block and the dose response curve for membrane depolarization in INS-1 cells (Fig. 1) . In the whole cell voltageclamp mode, an alternating voltage-step protocol (stepping to 250 mV or 290 mV from a holding potential of 270 mV) elicited inward (at 290 mV) and outward (at 250 mV) K 1 currents through K ATP channels (Fig. 1A) . These currents were blocked by increasing concentrations of either sulfonylurea drug, as indicated by the decrease in current amplitude in both directions. Plots of the percent of current block at each of several different concentrations of either tolbutamide or gliclazide yielded dose response curves that were fit as described in Materials and Methods. As expected, gliclazide was more potent in blocking of K ATP channel current than was tolbutamide (gliclazide IC 50 5 143 6 23 nM; tolbutamide IC 50 5 2.6 6 0.7 mM; Fig. 1B) .
Because the block of K ATP channels leads to membrane depolarization in pancreatic beta cells, we also measured the dose dependence for the membrane depolarization induced by tolbutamide or gliclazide. In current-clamp recordings using the zero-current injection mode, the resting membrane potential of INS-1 cells was found to be 275.1 6 0.75 mV. Application of high concentrations of either tolbutamide (500 mM) or gliclazide (200 mM) caused similar, strong depolarization of the membrane potential that often led to firing of action potentials at voltages greater than 250 mV (Fig. 1C) . Membrane potential repolarization occurred rapidly upon washout of tolbutamide. Washout of gliclazide was slower, but could be accelerated by application of 300 mM diazoxide, a K ATP channel "opener" (Fig. 1C) . To compare the potency of tolbutamide and gliclazide in stimulating membrane potential depolarization, increasing concentrations of either drug were applied to INS-1 cells under current clamp. Tolbutamide and gliclazide both led to progressively greater depolarization of the membrane potential (Fig. 1D ). Similar to block of K ATP channel current, gliclazide induced membrane depolarization more potently than did tolbutamide. The EC 50 for membrane depolarization by tolbutamide was determined to be 21.5 6 10 mM with a maximum depolarization of 27.1 6 4.2 mV. The EC 50 for membrane depolarization by gliclazide was determined to be 4.2 6 0.9 mM with a maximum depolarization of 32.6 6 3.8 mV. Because the concentrations of 20 mM gliclazide and 200 mM tolbutamide were maximally effective in their ability to induce membrane depolarization and were within error of each other, we used these concentrations for subsequent experiments to compare the ability of these sulfonylurea drugs to stimulate activities in INS-1 cells.
Stimulation of Insulin Secretion and Ca 21 Transients by Tolbutamide and Gliclazide. The concentrations of 20 mM gliclazide and 200 mM tolbutamide were used to induce insulin secretion in INS-1 cells using the static incubation method (Fig. 2) . As expected from the electrophysiological characterization of the drugs, these concentrations of the sulfonylureas stimulated insulin secretion that was significantly different from basal secretion. Secretion stimulated by both 20 mM gliclazide and 200 mM tolbutamide was completely inhibited by 2 mM nicardipine, an L-type-selective Ca 21 channel blocker ( Fig. 2A) . Nicardipine was used at 2 mM because we had shown previously that it completely inhibits L-type channels but does not substantially inhibit P/Q-type Ca 21 channels at this concentration (Lin et al., 2011) . To assess the role of internal stores of Ca 21 in sulfonylureastimulated insulin secretion, the ability of 1 mM thapsigargin, an inhibitor of the sarcoplasmic/endoplasmic reticulum Ca 21 -ATPase (SERCA), to inhibit insulin secretion stimulated by either gliclazide or tolbutamide was determined. We found that thapsigargin completely inhibited secretion stimulated by 20 mM gliclazide and significantly, but incompletely, blocked insulin secretion stimulated by 200 mM tolbutamide (Fig. 2B) (Fig. 3A) , we found that significant potentiation of the response occurred at concentrations $2.0 mM as well. The potentiation of secretion over that stimulated by gliclazide alone was 1.47-fold and 2.1-fold at 2 mM and 5 mM 8-pCPT-29-O-Me-cAMP-AM, respectively. Moreover, the insulin secretion stimulated by 200 mM tolbutamide (199.3 6 13 ng insulin/mg protein; n 5 14) 
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is not significantly different from that stimulated by 20 mM gliclazide (237 6 13 ng insulin/mg protein; n 5 12). 8-pCPT-29-O-Me-cAMP-AM at concentrations up to 5 mM had no effect on insulin secretion in the absence of sulfonylurea (basal 5 121 6 8 ng insulin/mg protein, 5 mM 8-pCPT-29-O-Me-cAMP-AM only 5 156 6 6 ng insulin/mg protein; n 5 9 in three separate experiments). Thus the concentration dependence and extent of potentiation of both 200 mM tolbutamide and 20 mM gliclazide-stimulated insulin secretion by 8-pCPT-29-OMe-cAMP-AM are essentially identical.
To ensure that the potentiation of insulin secretion by 8-pCPT-29-O-Me-cAMP-AM that we observed with both tolbutamide and gliclazide was not mediated by cross-activation of protein kinase A (PKA), we tested the ability of the PKA-specific inhibitor Rp-adenosine-39,59-cyclic monophosphorothioate (Rp-cAMPs) to inhibit the potentiation of sulfonylurea-stimulated insulin secretion by 8-pCPT-29-OMe-cAMP-AM. As shown in Fig. 3B , 100 mM Rp-cAMPs did not significantly inhibit the potentiation of either tolbutamide-or gliclazide-stimulated insulin secretion by 5 mM 8-pCPT-29-O-Me-cAMP-AM. However, 2 mM nicardipine completely blocked insulin secretion stimulated by tolbutamide or gliclazide in the presence of 5 mM 8-pCPT-29-O-MecAMP-AM (Fig. 3C) Activation of Phospholipase C by Tolbutamide or Gliclazide in INS-1 Cells. Because tolbutamide, but not gliclazide, is reported to directly activate EPAC2, we compared the ability of gliclazide and tolbutamide to stimulate phospholipase C activity in these cells. The concentrations of inositol-1-phosphate (IP 1 ) in the presence of LiCl [to inhibit inositol-1-phosphate phosphatase (Hallcher and Sherman, 1980) ] after stimulation with the muscarinic receptor agonist carbachol (500 mM) was measured in INS-1 cells using homogeneous time-resolved FRET (HTRF). Muscarinic acetylcholine receptor agonists, such as carbachol, stimulate phospholipase C activity in pancreatic beta cells (Yada et al., 1995) and INS-1 cells (Jacobo et al., 2009 ). The phospholipase † † P , 0.01, † P , 0.05 compared with sulfonylurea and sulfonylurea + all concentrations of 8-pCPT-29-O-Me-cAMP-AM; ***P , 0.001, *P , 0.05 compared with sulfonylurea alone (n = 9-14 in 3-5 independent experiments). (B) potentiation of tolbutamide-and gliclazide-stimulated insulin secretion by 8-pCPT-29-O-Me-cAMP-AM is not blocked by the selective PKA inhibitor Rp-cAMPs (100 mM). ***P , 0.001 compared with sulfonylurea alone; sulfonylurea and ESCA +/2 Rp-cAMPs were not significantly different (P = 0.089 for Tolb, P = 0.91 for Glz) (n = 9 in 3 independent experiments). (C) potentiation of tolbutamide-and gliclazide-stimulated insulin secretion by 5 mM 8-pCPT-29-O-Me-cAMP-AM is completely blocked by the L-type Ca 2+ channel blocker nicardipine (2 mM). ***P , 0.001, **P , 0.01, *P , 0.05 compared with basal (n = 9 in 3 independent experiments).
C inhibitor U73122 and its inactive analog U73343 were used to define specific phospholipase C activity stimulated by 500 mM carbachol, 200 mM tolbutamide, or 20 mM gliclazide in the HTRF assay for IP 1 . As shown in Fig. 5A , 500 mM carbachol stimulated IP 1 accumulation in INS-1 cells that was completely blocked by either 100 mM atropine, a muscarinic receptor antagonist, or 10 mM U73122, but not 10 mM U73343. Stimulation of INS-1 cells with 200 mM tolbutamide or 20 mM gliclazide also resulted in a significant increase in IP 1 accumulation over basal levels that was completely inhibited by 10 mM U73122, but not 10 mM U73343 (Fig. 5 , B and C). Although U73122 and U73343 gave the expected results in our experiments measuring IP 1 accumulation, we did not use these compounds in experiments measuring changes in intracellular Ca 21 concentration because we found that 10 mM U73122 irreversibly blocks ∼80% and 10 mM U73343 reversibly blocks ∼50% of the voltage-gated Ca 21 channel activity in INS-1 cells (Supplemental Fig. 1) .
Because membrane depolarization is reported to stimulate phospholipase C activity in INS-1 cells (Thore et al., 2004) , we further asked if carbachol, tolbutamide, or gliclazide could stimulate IP 1 accumulation in the presence of the K ATP channel opener diazoxide. As expected, 500 mM carbachol stimulated a significant increase in IP 1 accumulation over basal levels that was completely blocked by 100 mM atropine in the presence or absence of 300 mM diazoxide (Fig. 5D) . However, diazoxide incompletely, but significantly, reduced the IP 1 accumulation stimulated by carbachol, suggesting that membrane depolarization contributes to carbachol activation of phospholipase C activity. In contrast, diazoxide completely inhibited the ability of 200 mM tolbutamide to stimulate IP 1 accumulation above basal levels (Fig. 5E) . Similar to what was observed with carbachol, 20 mM gliclazide significantly stimulated IP 1 accumulation over basal levels in the presence or absence of diazoxide, although this increase was significantly greater in the absence of diazoxide (Fig. 5F ). To ensure that membrane potential depolarization was not contributing to the diazoxide-resistant IP 1 accumulation observed with gliclazide, we measured the membrane potential in INS-1 cells stimulated with either 200 mM tolbutamide or 20 mM gliclazide and subsequently treated with 300 mM diazoxide in the continued presence of sulfonylurea drug. Figure 5G shows representative traces of whole cell current-clamp recordings of INS-1 cells depolarized with 200 mM tolbutamide (Fig. 5G, left) or 20 mM gliclazide (Fig. 5G, right) . After the membrane depolarization induced by each drug had reached its maximum, 300 mM diazoxide was coapplied with the sulfonylureas. With both tolbutamide and gliclazide, the resting membrane potential was rapidly re-established when 300 mM diazoxide was present. Figure 5H summarizes the results of five or six separate experiments with 200 mM tolbutamide or 20 mM gliclazide and 300 mM diazoxide and shows that the membrane potential in the presence of diazoxide and tolbutamide or gliclazide is not different from the resting membrane potential before application of either sulfonylurea drug. Taken together, our results show that gliclazide, but not tolbutamide, is capable of stimulating phospholipase C activity independently of its K ATP channel-blocking activity.
Evidence That Gliclazide Stimulates a Ga i/o ProteinCoupled Receptor. One possibility that might explain the K ATP channel-independent activity of gliclazide is that it activates a G protein-coupled receptor that can stimulate phospholipase C activity. Therefore, we asked whether pertussis toxin, an inhibitor of Ga i/o function, could interfere with the gliclazide stimulation of phospholipase C activity in the presence of diazoxide. Figure 6A shows that pretreatment of INS-1 cells in 96-well plates with 25 ng/well of pertussis toxin for 18 hours at 37°C, 5% CO 2 significantly, but incompletely, inhibited the ability of 20 mM gliclazide to stimulate IP 1 accumulation in the presence of 300 mM diazoxide. Increasing the amount of pertussis toxin used in the pretreatment to 50 ng/well did not further increase the extent of inhibition (data not shown). In contrast, pertussis toxin pretreatment had no effect on basal IP 1 levels in the presence of 300 mM diazoxide (Fig. 6A) . If gliclazide is, in fact, able to stimulate phospholipase C activity in the absence of membrane depolarization via activation of a Ga i/o -coupled receptor, then gliclazide should also stimulate a Ca concentration in the presence of diazoxide was clearly detectable. The magnitude of the response (area under the curve) to gliclazide in the presence of diazoxide was significantly greater than that stimulated by 200 mM tolbutamide under the same conditions (Fig. 6B, inset) .
We Fig. 6D ; ryanodine-sensitive: white circles). We next tested the requirement for physiologic concentrations of extracellular Ca 21 in the ryanodine-resistant transients stimulated by gliclazide. Figure 6E shows that in KRBH with zero added Ca 21 , 20 mM gliclazide was still able to stimulate a robust increase in intracellular Ca 2 concentration in the presence or absence of 20 mM ryanodine. To examine a possible role of Ga i/o -coupled receptors in this gliclazide-stimulated, ryanodineinsensitive Ca 21 transient, we pretreated INS-1 cells in 96-well plates with 25 ng/well of pertussis toxin (PTx) for 18 hours at 37°C, 5% CO 2 and measured the Ca 21 transients stimulated by summarized data comparing the resting membrane potential (Con), the membrane potential in the presence of the indicated sulfonylurea (SU), and membrane potential in the presence of sulfonylurea and 300 mM diazoxide (SU+Diaz). Tolbutamide: Con = 267.9 6 2 mV; SU = 234.3 6 5 mV; DU + Diaz = 267.3 6 2 mV (n = 5-6). Gliclazide: Con = 267.4 6 3 mV; SU = 231.5 6 5 mV; DU + Diaz = 264.8 6 2 mV (n = 5-6). ***P , 0.001 compared with control or SU + Diaz. 20 mM gliclazide in the presence of 20 mM ryanodine. A representative of six independent experiments is shown in Fig. 6F . Area under the curve analysis of these six experiments, normalized to the gliclazide response, revealed that PTx pretreatment did not significantly reduce the ability of gliclazide to stimulate a rise in intracellular Ca 21 concentration in the presence of ryanodine. Together, the data in Fig. 6 suggest that gliclazide stimulates phospholipase C activity independently of K ATP channel block and that this activity is, in part, mediated by a Ga i/o -dependent mechanism. This unique activity of gliclazide is correlated with stimulation of a more 21 Channel Activity in INS-1 Cells. To further elicit the mechanism of 8-pCPT-29-O-Me-cAMP potentiation of insulin secretion stimulated by tolbutamide or gliclazide in INS-1 cells, we used whole cell current-clamp measurements of membrane potential depolarization induced by these sulfonylureas in the presence or absence of 8-pCPT-29-O-Me-cAMP. In these experiments 5 mM 8-pCPT-29-O-Me-cAMP, not the acetoxymethyl ester, was included in the pipette solution and allowed to dialyze into the cells for 10 min before either 200 mM tolbutamide or 20 mM gliclazide was applied via bath perfusion. We found that addition of 5 mM 8-pCPT-29-O-MecAMP to the pipette solution did not significantly alter the extent of membrane potential depolarization induced by either sulfonylurea (Fig. 7A) . The effect of 5 mM 8-pCPT-29-O-Me-cAMP dialysis into the cells on whole cell voltage-gated Ca 21 channel currents was also assessed. Addition of 5 mM 8-pCPT-29-O-Me-cAMP to the pipette solution did not change the Ba 21 current density or the voltages at which whole cell . However, reducing extracellular Ca 2+ significantly reduced the Ca 2+ transients stimulated by Glz alone or Glz + Ryn (P , 0.05 and P , 0.01, respectively; not shown). (F) ryanodine-resistant Ca 2+ transient stimulated by gliclazide is not inhibited by PTx. Increase in fura2 340 nm/380 nm ratio in response to application of 20 mM gliclazide to INS-1 cells preincubated with KRBH only (black circles), 20 mM Ryn (white circles), or 20 mM Ryn after an 18 hours of pretreatment with PTx (gray diamonds). Data from cells pretreated with PTx only were omitted for clarity. Data shown are mean 6 S.E. and are representative of six independent experiments performed in quadruplicate. Area under the curve analysis of six independent experiments revealed no significant difference between Glz alone, Glz + PTx, Glz + Ryn, or Glz + Ryn + PTx (not shown).
voltage-dependent Ba 21 currents activated, from a holding potential of 270 mV, at either 3 min or .10 min after break-in compared with control cells (Fig. 7, B and C) . However, an approximately 215 mV shift in the reversal potential of voltage-dependent Ba 21 current was observed after 10 minutes with 5 mM 8-pCPT-29-O-Me-cAMP in the pipette (Fig. 7C ). This shift in reversal potential was likely due to an increase in membrane permeability to the organic cation Nmethyl-D-glucamine (NMDG) present in the intracellular solution, because it was abolished by equalizing the NMDG concentration in the intracellular and extracellular solutions (Fig. 7C) . In contrast, no shift was observed in controls cells in which 0.1% DMSO (vehicle for 8-pCPT-29-O-Me-cAMP) was included in the intracellular solution. The kinetics of current activation and inactivation were also unaffected by 5 mM 8-pCPT-29-O-Me-cAMP as illustrated in Fig. 7D , which shows Ba 21 current measured at 0 mV from a holding potential of 2 70 mV, in a single cell, at break-in and 10 minutes after breakin. Thus Me-cAMP, applied via the patch pipette, did enhance membrane permeability to the organic cation NMDG.
Activation of Phospholipase C Activity by 8-pCPT-29-O-Me-cAMP-AM. Because activation of EPAC2 leads to activation of PLC-« via Rap1 , we examined the ability of the concentrations of 8-pCPT-29-OMe-cAMP-AM that gave significant potentiation of insulin secretion by tolbutamide or gliclazide to stimulate an increase in cellular phospholipase C activity. As expected, 500 mM carbachol stimulated an increase in IP 1 accumulation in INS-1 cells that was completely blocked by 100 mM atropine (Fig.  8A) . Concentrations of 8-pCPT-29-O-Me-cAMP-AM from 1-20 mM did not stimulate IP 1 accumulation above the basal level. However, 50 mM 8-pCPT-29-O-Me-cAMP-AM applied to INS-1 cells significantly increased IP 1 accumulation to an extent that was not different from that stimulated by 500 mM carbachol (Fig. 8A) . Because 5 mM 8-pCPT-29-O-Me-cAMP-AM was sufficient to strongly potentiate both insulin secretion and Ca 21 transients stimulated by tolbutamide or gliclazide, we looked for other evidence that 5 mM 8-pCPT-29-O-Me-cAMP-AM could, in fact, stimulate phospholipase C activity. If the HTRF assay for IP 1 is not sensitive enough to detect very low concentrations of IP 1 generated by 5 mM 8-pCPT-29-O-Me-cAMP-AM, we reasoned that a small rise in Fig. 7 . Effect of intracellular application of the EPAC-selective cAMP analog (ESCA) 8-pCPT-29-O-Me-cAMP on sulfonylurea-stimulated membrane depolarization and voltage-dependent Ca 2+ channel activity in INS-1 cells. (A) membrane potential changes measured using whole cell current clamp during application of tolbutamide or gliclazide in the absence (black bars) or presence (gray bars) of 5 mM 8-pCPT-29-O-Me-cAMP (ESCA) (n = 6-10). 8-pCPT-29-O-Me-cAMP was included in the intracellular solution of the patch pipette, and the cell was held for at least 10 min to allow for equilibration of 8-pCPT-29-O-Me-cAMP into the cell. After 10 minutes, tolbutamide or gliclazide was applied and changes in membrane potential were recorded. (B) whole cell IBa density (pA/pF) measured at 0 mV from a holding potential of 270 mV using whole cell voltage clamp. 8-pCPT-29-O-Me-cAMP (5 mM) was included in the intracellular solution of the patch pipette. Once consistent, currents were recorded 3 minutes after break-in and then again 10 minutes after break-in. (n = 11). (C) current-voltage relationship curves of IBa measured using whole cell voltage clamp. Currents were elicited by 100-ms depolarizations from 250 to +60 mV in 10-mV increments, from a holding potential of 270 mV, in the absence (control, gray triangles) or presence of 5 mM 8-pCPT-29-O-Me-cAMP in the patch pipette 3 minutes (black circles) or 10 minutes (gray circles) after break-in (n = 15). The shift in reversal potential observed .10 min after break-in with 8-pCPT-29-O-Me-cAMP in the patch pipette is abolished when the concentration of N-methyl-Dglucamine (NMDG) is equalized on both sides of the membrane by replacing 130 mM of Tris in the extracellular solution with 130 mM NMDG (black triangles) (n = 6). The shift in reversal potential is not observed at .10 minutes after break-in when 0.1% DMSO only (vehicle; gray triangles) is added to the intracellular solution. (D) representative whole cell voltage clamp trace of IBa measured at 0 mV, from a holding potential of 270 mV, with 5 mM of 8-pCPT-29-O-Me-cAMP at 3 min after break-in (control) or 10 min after break-in in the same INS-1 cell. intracellular Ca 21 stimulated by low levels of phospholipase C activation might be detectable. Therefore, we applied increasing concentrations of 8-pCPT-29-O-Me-cAMP-AM to fura2-loaded INS-1 cells and measured the change in 340 nm/380 nm ratio over 8-10 minutes. This longer time scale was used because 8-pCPT-29-O-Me-cAMP-AM must be deesterified intracellularly before it becomes active. We found that 8-pCPT-29-O-Me-cAMP-AM dose dependently increased intracellular Ca 21 concentrations and that a significant increase over basal was observed at concentrations as low as 2 mM and 5 mM (Fig. 8B) . The rise in intracellular Ca 21 stimulated by 5 mM 8-pCPT-29-O-Me-cAMP-AM was significantly blocked by preincubation of cells with 25 mM 2-aminoethoxydiphenylborate (2-APB) (Fig. 8C) . Because 2-APB is able to block both IP 3 receptors and TRP channels (Bootman et al., 2002) , we examined the ability of 5 mM 8-pCPT-29-OMe-cAMP-AM to stimulate Ca 21 transients in the absence of extracellular Ca 21 . We found that 5 mM 8-pCPT-29-O-MecAMP-AM stimulation of Ca 21 transients in INS-1 cells was abolished by removal of Ca 21 from the extracellular solution (Fig. 8C) . Thus, even though we were unable to detect an increase in IP 1 levels stimulated by 5 mM 8-pCPT-29-OMe-cAMP-AM, it does stimulate a small, but detectable, increase in intracellular Ca 21 that could mediate the potentiation of sulfonylurea action.
Because 2-APB inhibits the 8-pCPT-29-O-Me-cAMP-AMstimulated increase in intracellular Ca 21 concentration, we tested the ability of 2-APB to inhibit 8-pCPT-29-O-MecAMP-AM potentiation of tolbutamide-stimulated insulin secretion. We chose tolbutamide over gliclazide for these experiments to avoid the K ATP channel-independent activity of gliclazide. As shown in Fig. 8D , 5 mM 8-pCPT-29-O-MecAMP-AM increased insulin secretion stimulated by 200 mM tolbutamide by approximately twofold, whereas addition of 25 mM 2-APB alone did not significantly affect tolbutamide-stimulated insulin secretion . However, when INS-1 cells were treated with 25 mM 2-APB 1 5 mM 8-pCPT-29-O-Me-cAMP-AM, tolbutamide-stimulated insulin secretion was not different from that measured in the absence of either compound. Thus, 25 mM 2-APB significantly blocked both the increase in intracellular Ca 21 concentration and the potentiation of tolbutamide-stimulated insulin secretion stimulated by 5 mM 8-pCPT-29-O-Me-cAMP-AM in INS-1 cells. (Oestreich et al., 2009) . We therefore examined the ability of the broad-spectrum PKC inhibitor bisindolylmaleimide I (BIS) to inhibit potentiation of tolbutamide action by 8-pCPT-29-O-Me-cAMP-AM (Fig. 9) . As shown in Fig (Fig. 9C) . In contrast to the experiments measuring Ca 21 transients, the combination of 1 mM BIS 1 5 mM 8-pCPT-29-O-Me-cAMP-AM potentiated insulin secretion stimulated by tolbutamide to a greater extent than 1 mM BIS alone (Fig. 9D) . Because inhibition of PKC potentiates both tolbutamide-stimulated Ca 21 transients and insulin secretion, it is unlikely that activation of PKC by EPAC2/Rap1 stimulation of phospholipase C activity plays a role in the potentiation of sulfonylurea-stimulated Ca 21 transients or insulin secretion.
Discussion
Potentiation of Tolbutamide-or Gliclazide-stimulated Insulin Secretion and Ca 21 Transients by the EPACselective cAMP Analog 8-pCPT-29-O-Me-cAMP Is Not Different in INS-1 Cells. Previous studies reported that the sulfonylurea tolbutamide is able to directly activate EPAC2 while the structurally distinct sulfonylurea gliclazide is not . We tested this conclusion in the rat pancreatic b-cell line INS-1 using a pharmacological approach. If tolbutamide activates EPAC2 in INS-1 cells, we Data shown are mean 6 S.E. for three separate experiments (n = 9). ***P , 0.001, **P , 0.01. (C) potentiation of tolbutamide-stimulated insulin secretion by 1 mM BIS. Insulin secretion stimulated by 200 mM tolbutamide in the presence of 1 mM BIS was significantly greater than that stimulated by 200 mM tolbutamide alone. Insulin secretion in the presence of 1 mM BIS alone was not different from basal. Data shown are mean 6 S.E. for three separate experiments (n = 9). ***P , 0.001, **P , 0.01 compared with basal; would expect that tolbutamide might stimulate insulin secretion to a greater extent than gliclazide at concentrations of the drugs that are equivalent in terms of their activity at the K ATP channels. In fact, we found that at such concentrations, tolbutamide and gliclazide stimulated insulin secretion to the same extent (Fig. 3A) . In addition, if tolbutamide was able to activate EPAC2 directly in INS-1 cells, we would expect that gliclazide-stimulated secretion would be more sensitive to potentiation by 8-pCPT-29-O-Me-cAMP-AM. However, we found that the concentration at which 8-pCPT-29-OMe-cAMP-AM potentiation of insulin secretion reached significance was identical for both sulfonylureas (i.e., 2 mM; Fig. 3A ). In addition, the Ca 21 transient stimulated by either sulfonylurea was significantly potentiated by 8-pCPT-29-OMe-cAMP-AM at 5 mM, but not at 1 mM (Fig. 4) . These findings are inconsistent with a direct activation of EPAC2 by 200 mM tolbutamide, but not 20 mM gliclazide, in INS-1 cells.
8-pCPT-29-O-Me-cAMP Potentiation of SulfonylureaStimulated Insulin Secretion and Ca 21 Transients Does Not Require Activation of PKA or Enhancement of Membrane Depolarization. The mechanism by which 8-pCPT-29-O-Me-cAMP-AM potentiates insulin secretion by sulfonylureas was also examined. The concentrations of 8-pCPT-29-O-Me-cAMP-AM used in this study are very likely to be selective for activation of EPAC over PKA because even 1 mM 8-pCPT-29-O-Me-cAMP activated ,25% of PKA activity at physiologic concentrations of the enzyme (Christensen et al., 2003) . However, sulfonylurea stimulation of pancreatic b-cells has been reported to stimulate adenylyl cyclase activity (Grill and Cerasi, 1978) . Therefore, endogenously produced cAMP, and activation of PKA, could potentially contribute to the activities of tolbutamide and gliclazide observed in this study. To test this possibility, we asked if the PKA-selective inhibitor Rp-cAMPs could interfere with 8-pCPT-29-O-Me-cAMP-AM potentiation of sulfonylurea-stimulated insulin secretion; however, a role for PKA activity was excluded because 100 mM Rp-cAMPs had no effect (Fig. 3) . This result contrasts with a previous report that potentiation of glucose-stimulated insulin secretion by 8-pCPT-29-O-MecAMP-AM was markedly attenuated by inhibitors of PKA in human islets . This discrepancy may result from differences between glucose stimulation of b-cells, which generates many glucose metabolites, and sulfonylurea stimulation, which more specifically regulates membrane potential.
A previous study (Leech et al., 2010b) found that 8-pCPT-29-O-Me-cAMP-AM at concentrations of 10 mM and 50 mM increased the sensitivity of K ATP channels in excised membrane patches to relatively low concentrations of tolbutamide. However, as channel block by tolbutamide approached saturation, this effect of 8-pCPT-29-O-Me-cAMP-AM became insignificant. Our analysis of the electrophysiological effects of 5 mM 8-pCPT-29-O-Me-cAMP-AM on INS-1 cells did not reveal any potentiation of sulfonylurea-induced membrane depolarization or any enhancement of voltage-gated Ca 21 channel activity (Fig. 7) . This is not surprising given that the concentrations of sulfonylureas were saturating both in terms of their effect on membrane potential and in block of whole cell K ATP channel currents (Fig. 1) . Moreover, the concentration of 8-pCPT-29-O-Me-cAMP-AM used in the electrophysiological experiments reported here were lower than those used by Leech et al. (2010b) . Thus, the ability of (Fig. 2) stimulated by tolbutamide and gliclazide were both blocked by the L-type Ca 21 channel blocker nicardipine. Moreover, insulin secretion stimulated by both sulfonylureas was substantially blocked by unloading intracellular stores of Ca 21 with thapsigargin (Fig. 2) . Thapsigargin selectively inhibited the early peak of the Ca 21 transient stimulated by either tolbutamide or gliclazide (Fig. 2) . Interestingly, the major effect of 8-pCPT-29-O-Me-cAMP-AM on sulfonylurea-stimulated Ca 21 transients was to markedly increase the amplitude of this early peak (Fig. 4) Gliclazide, But Not Tolbutamide, Stimulates a Depolarization-independent Activation of Phospholipase C Activity in INS-1 Cells. If tolbutamide were able to directly activate EPAC2 and Rap1 in INS-1 cells, it may have a unique ability to activate phospholipase C-« and mobilize Ca 21 from internal stores via an RYR2-independent, phospholipase C/IP 3 receptor-dependent mechanism. We found, however, that both tolbutamide and gliclazide markedly stimulated phospholipase C activity as assessed by accumulation of IP 1 . It was previously reported that glucose stimulates phospholipase C activity that depends upon Ca 21 influx via L-type Ca 21 channels and protein kinase C activation in INS-1 cells (Thore et al., 2004) . However, our experiments measuring gliclazide-and tolbutamide-stimulated phospholipase C activity in the presence of diazoxide uncovered a unique ability of gliclazide to activate phospholipase C independently of its K ATP channel blocking activity (Fig. 5) . The mechanism accounting for this activity remains unknown. However, the unique activities of gliclazide that we have identified in this study, including its similarity to carbachol in stimulating IP 1 accumulation in the presence or absence of diazoxide, the partial sensitivity of this activity to pertussis toxin, the ability to stimulate a diazoxide-insensitive Ca 21 transient, and the ability to stimulate a ryanodine-insensitive Ca 21 transient in the presence or absence of physiologic concentrations of extracellular Ca 21 (Fig. 6 ), suggest that gliclazide may activate a GPCR that stimulates phospholipase C (Fig.  10A) . Attractive possibilities include cannabinoid or purinergic receptors. CB 1 and CB 2 receptors are present and coupled to activation of phospholipase C and Ca 21 mobilization in the rat pancreatic b-cell line Rinm5F (De Petrocellis et al., 2007) and mouse pancreatic b-cells . The CB 1 receptor inverse agonists rimonabant and ibipinabant are reported to act as K ATP channel openers (Lynch et al., 2012) at low micromolar concentrations, suggesting some similarity in the structural requirements for K ATP channel and CB 1 receptor modulation. Additionally, various subtypes of P 2 Y receptors are expressed in pancreatic beta cells, some of which activate PLC in response to binding of ATP and other nucleotides (Burnstock and Novak, 2012) . Alternatively, our data do not exclude the possibility that gliclazide has a direct effect on PLC activity that is synergistic with G i and is therefore partially inhibited by pertussis toxin. Whatever the mechanism, our results provide a potential explanation for some unique therapeutic advantages of gliclazide. For example, gliclazide carries a reduced risk for secondary beta cell failure in patients with type 2 diabetes compared with the sulfonylurea glibenclamide (Satoh et al., 2005) . In addition, two large clinical studies have reported a reduced risk of death by cardiovascular disease in type 2 diabetics taking gliclazide compared with similar patients taking other sulfonylureas including glibenclamide and tolbutamide (Jorgensen et al., 2010; Schramm et al., 2011) . Interestingly, gliclazide is reported to inhibit several activities of oxidized low-density lipoprotein in human endothelial cells (Li and Renier, 2009) and to reduce adhesion of monocytes to endothelial cells (Renier et al., 2003) -early steps in atherosclerosis. Determining whether these beneficial effects of gliclazide can be attributed to the non-K ATP channel-dependent activity reported here will clearly require further investigation.
The concentrations at which 8-pCPT-29-O-Me-cAMP-AM began to potentiate insulin secretion (2 mM) and the first phase of the Ca 21 transient stimulated by sulfonylureas (5 mM) were an order of magnitude below the lowest concentration of 8-pCPT-29-O-Me-cAMP-AM that activated phospholipase C as detected by the IP 1 assay (50 mM). A previous study reported activation of phospholipase C activity in INS-1 cells by 10 mM 8-pCPT-29-O-Me-cAMP-AM as detected by the translocation of a pleckstrin homology domain/GFP fusion (Leech et al., 2010b) . Our data argue that concentrations as low as 2 mM of 8-pCPT-29-O-Me-cAMP-AM stimulate PLC activity, which is sufficient to stimulate a rise in intracellular Ca 21 concentration, but below the level of detection of the IP 1 HTRF assay. The greater sensitivity of fluorescent Ca 21 indicators compared with the IP 1 HTRF assay in detecting the activation of phospholipase C was previously reported (Liu et al., 2008) . The 8-pCPT-29-OMe-cAMP-AM-stimulated Ca 21 rise is sensitive to both 2-APB and removal of extracellular Ca
21
, suggesting that influx of Ca 21 via a TRP channel may be involved (Fig. 10B) . Indeed, inclusion of 5 mM 8-pCPT-29-O-Me-cAMP in the pipette solution during voltage-clamp experiments activated an NMDG conductance in the plasma membrane of INS-1 cells (Fig. 7C) . Interestingly, several members of the TRP superfamily of cation channels are reported to conduct NMDG, including TRPC (Hillyard et al., 2010) , TRPA (Banke et al., 2010) , and TRPV (Chung et al., 2008) . TRPC channel subtypes are attractive candidates for this activity because they are blocked by 2-APB (Birnbaumer, 2009 ) and many are positively regulated by PLC activity (Beech, 2012) . Interestingly, TRPC1 and TRPC4 are expressed in INS-1 cells and rat b-cells (Li and Zhang, 2009) , and TRPC4 is expressed in bTC3 cells (Qian et al., 2002) .
In summary, our data show that insulin secretion and Ca 21 transients stimulated by gliclazide or tolbutamide are potentiated equally by the EPAC selective cAMP analog 8-pCPT-29-O-Me-cAMP in INS-1 cells. However, gliclazide, but not tolbutamide, exhibits K ATP channel-independent stimulation of phospholipase C activity that is mediated, in part, by a Ga i/O -dependent mechanism. Uncovering differences in activities between gliclazide and other sulfonylureas is of therapeutic relevance because gliclazide has shown some clinical advantages over other second generation drugs. Our data also suggest a potential role for activation of a 2-APBsensitive Ca 21 influx in the EPAC-dependent potentiation of sulfonylurea-stimulated insulin secretion in INS-1 cells. It will be of interest to further characterize this Ca 21 flux and identify the channel by which it is conducted.
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Wrote or contributed to the writing of the manuscript: Hockerman. -induced Ca 2+ release from the ER and insulin secretion. Membrane depolarization (this study) and Ca 2+ influx (Mogami et al., 2003; Jacobo et al., 2009 ) is also apparently coupled to activation of a phospholipase C activity. When membrane potential depolarization is prevented with diazoxide, the unique ability of gliclazide to activate PLC via a mechanism that is partially mediated by Ga i/O is unmasked. The observation that PTx only partially inhibits gliclazide-stimulated PLC activity in the presence of diazoxide suggests that another G protein (presumably Ga q/11 ) is also involved. We hypothesize that gliclazide is an agonist at an as of yet unidentified G protein-coupled receptor. (B) model for EPAC-mediated potentiation of sulfonylurea action. Binding of cAMP to EPAC2 activates PLC-« via Rap1 , leading to an influx of Ca 2+ that can greatly amplify Ca 2+ -induced Ca 2+ release and insulin secretion stimulated by sulfonylureas. TRPC channels are proposed as potential effectors of EPAC2 /Rap1 activation based upon their sensitivity to 2-APB and activation via a PLC-dependent mechanism.
